Table 2.

Correlation of the severity of the post-vaccinal reactions and different parameters.

Variable	Don't have side effect	Mild	Moderate	Severe	Critical	Significance and correlation
Sex, n (%)
Female	227 (7.9)	1,262 (43.9)	887 (30.9)	471 (16.4)	27 (0.9)	P < 0.015
Male	210 (16.2)	615 (47.5)	311 (24.0)	148 (11.4)	12 (0.9)	R = −0.133
Age groups, n (%)
<20	82 (12.2)	277 (41.3)	207 (30.8)	96 (14.3)	9 (1.3)	P < 0.016
20–30	158 (8.0)	874 (44.5)	604 (30.7)	314 (16.0)	15 (0.8)	R = −0.069
31–40	69 (10.3)	316 (47.1)	177 (26.4)	105 (15.6)	4 (0.6)
41–50	69 (11.9)	283 (48.6)	143 (24.6)	79 (13.6)	8 (1.4)
51–60	41 (18.1)	105 (46.3)	58 (25.6)	21 (9.3)	2 (0.9)
> 60	18 (33.3)	22 (40.7)	9 (16.7)	4 (7.4)	1 (1.9)
Nationality, n (%)
Saudi	410 (10.5)	1,776 (45.5)	1,113 (28.5)	565 (14.5)	36 (0.9)	P < 0.016
Non Saudi	27 (10.0)	101 (37.4)	85 (31.5)	54 (20.0)	3 (1.1)	R = 0.042
BMI, n (%)
<18.5	42 (9.6)	197 (45.2)	125 (28.7)	68 (15. 6)	4 (0.9)	P < 0.0.16
18.5–24.9	162 (9.4)	744 (43.2)	520 (30.2)	282 (16.4)	13 (0.8)	R = −0.040
25–29.9	133 (12.1)	500 (45.4)	317 (28.8)	140 (12.7)	12 (1.1)
30–34.9	56 (9.8)	274 (47.8)	149 (26.0)	89 (15.5)	5 (0.9)
35–39.9	29 (12.6)	121 (52.4)	55 (23.8)	24 (10.4)	2 (0.9)
≥40	15 (14.0)	41 (38.3)	32 (29.9)	16 (15.0)	3 (2.8)
Type of the vaccine
BNT162b2 (n:2601)	375 (14.42)	1,423 (54.71)	616 (23.68)	171 (6.57)	16 (0.62)	P < 0.01
ChAdOx1 (n = 1,569)	62 (3.95)	454 (28.93)	582 (37.09)	448 (28.55)	23 (1.47)	R = 0.381
Previous infection with COVID-19, n (%)
No	385 (10.5)	1,681 (45.8)	1,040 (28.3)	528 (14.4)	39 (1.1)	P < 0.016
Yes	52 (10.5)	196 (39.4)	158 (31.8)	91 (18.3)	0 (0.0)	R = 0.035
The presence of chronic diseases, n (%)
No	356 (10.3)	1564 (45.4)	1014 (29.4)	486 (14.1)	27 (0.8)	P < 0.016
Yes	81 (11.2)	313 (43.3)	184 (25.4)	133 (18.4)	12 (1.7)	R = 0.20